IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 222-230

  Luther, Gaurav A ^a   Lamplot, Joseph ^a   Chen, Xiang ^a,b   Rames, Richard ^a   Wagner, Eric R ^a   Liu, Xing ^a,c   Parekh, Akash ^a   Huang, Enyi ^a,d   Kim, Stephanie H ^a   Shen, Jikun ^a   Haydon, Rex C ^a   He, Tong Chuan ^a,c   Luu, Hue H ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; IGFBP5; Insulin like growth factor binding protein; Metastasis; Osteosarcoma

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 5;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METASTASIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; PHENOTYPE; PROTEIN INTERACTION DOMAINS AND MOTIFS; TIME FACTORS;

ANIMALIA;

EID: 84878961154     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.002     Document Type: Article

References (35)

1. Whelan J.S. Osteosarcoma. Eur. J. Cancer 1997, 33:1611-1618. Discussion 1618-9.
2. Kaste S.C., Pratt C.B., Cain A.M., Jones-Wallace D.J., Rao B.N. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 1999, 86:1602-1608.
3. Yonemoto T., Tatezaki S., Ishii T., Satoh T., Kimura H., Iwai N. Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin. Orthop. 1998, 194-199.
4. Davis A.M., Bell R.S., Goodwin P.J. Prognostic factors in osteosarcoma: a critical review. J. Clin. Oncol. 1994, 12:423-431.
5. Mankin H.J., Hornicek F.J., Rosenberg A.E., Harmon D.C., Gebhardt M.C. Survival data for 648 patients with osteosarcoma treated at one institution. Clin. Orthop. 2004, 286-291.
6. Letson G.D., Muro-Cacho C.A. Genetic and molecular abnormalities in tumors of the bone and soft tissues. Cancer Control 2001, 8:239-251.
7. Ragland B.D., Bell W.C., Lopez R.R., Siegal G.P. Cytogenetics and molecular biology of osteosarcoma. Lab. Invest. 2002, 82:365-373.
8. Fuchs B., Pritchard D.J. Etiology of osteosarcoma. Clin. Orthop. 2002, 40-52.
9. Su Y., Wagner E.R., Luo Q., Huang J., Chen L., He B.C., Zuo G.W., Shi Q., Zhang B.Q., Zhu G., Bi Y., Luo J., Luo X., Kim S.H., Shen J., Rastegar F., Huang E., Gao Y., Gao J.L., Yang K., Wietholt C., Li M., Qin J., Haydon R.C., He T.C., Luu H.H. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 2011, 30:3907-3917.
10. Su Y., Luo X., He B.C., Wang Y., Chen L., Zuo G.W., Liu B., Bi Y., Huang J., Zhu G.H., He Y., Kang Q., Luo J., Shen J., Chen J., Jin X., Haydon R.C., He T.C., Luu H.H. Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin. Exp. Metast. 2009, 26:599-610.
11. Rosenzweig S.A. What's new in the IGF-binding proteins?. Growth Horm. IGF Res. 2004, 14:329-336.
12. Mukherjee A., Rotwein P. Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?. Growth Horm. IGF Res. 2007, 17:179-185.
13. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 1998, 95:2509-2514.
14. Kang Q., Song W.X., Luo Q., Tang N., Luo J., Luo X., Chen J., Bi Y., He B.C., Park J.K., Jiang W., Tang Y., Huang J., Su Y., Zhu G.H., He Y., Yin H., Hu Z., Wang Y., Chen L., Zuo G.W., Pan X., Shen J., Vokes T., Reid R.R., Haydon R.C., Luu H.H., He T.C. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev. 2009, 18:545-559.
15. Kang Q., Sun M.H., Cheng H., Peng Y., Montag A.G., Deyrup A.T., Jiang W., Luu H.H., Luo J., Szatkowski J.P., Vanichakarn P., Park J.Y., Li Y., Haydon R.C., He T.C. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 2004, 11:1312-1320.
16. Luo J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., Sharff K.A., Luu H.H., Haydon R.C., Kinzler K.W., Vogelstein B., He T.C. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2007, 2:1236-1247.
17. Luo X., Sharff K.A., Chen J., He T.C., Luu H.H. S100A6 expression and function in human osteosarcoma. Clin. Orthop. Relat. Res. 2008, 466:2060-2070.
18. Luu H.H., Zhou L., Haydon R.C., Deyrup A.T., Montag A.G., Huo D., Heck R., Heizmann C.W., Peabody T.D., Simon M.A., He T.C. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett. 2005, 229:135-148.
19. Luu H.H., Kang Q., Park J.K., Si W., Luo Q., Jiang W., Yin H., Montag A.G., Simon M.A., Peabody T.D., Haydon R.C., Rinker-Schaeffer C.W., He T.C. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metast. 2005, 22:319-329.
20. Luo Q., Kang Q., Si W., Jiang W., Park J.K., Peng Y., Li X., Luu H.H., Luo J., Montag A.G., Haydon R.C., He T.C. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 2004, 279:55958-55968.
21. Peng Y., Kang Q., Luo Q., Jiang W., Si W., Liu B.A., Luu H.H., Park J.K., Li X., Luo J., Montag A.G., Haydon R.C., He T.C. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 2004, 279:32941-32949.
22. Luu H.H., Zagaja G.P., Dubauskas Z., Chen S.L., Smith R.C., Watabe K., Ichikawa Y., Ichikawa T., Davis E.M., Le Beau M.M., Rinker-Schaeffer C.W. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res. 1998, 58:3561-3565.
23. Manara M.C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P.L., Nanni C., Hofmann F., Garcia-Echeverria C., Picci P., Scotlandi K. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin. Cancer. Res. 2007, 13:1322-1330.
24. Avnet S., Sciacca L., Salerno M., Gancitano G., Cassarino M.F., Longhi A., Zakikhani M., Carboni J.M., Gottardis M., Giunti A., Pollak M., Vigneri R., Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009, 69:2443-2452.
25. Stolf B.S., Carvalho A.F., Martins W.K., Runza F.B., Brun M., Hirata R., Jordao Neves E., Soares F.A., Postigo-Dias J., Kowalski L.P., Reis L.F. Differential expression of IGFBP-5 and two human ESTs in thyroid glands with goiter, adenoma and papillary or follicular carcinomas. Cancer Lett. 2003, 191:193-202.
26. Cheung C., Vesey D., Cotterill A., Douglas M., Gobe G., Nicol D., Johnson D. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int. J. Urol. 2005, 12:17-28.
27. Takahashi M., Papavero V., Yuhas J., Kort E., Kanayama H.O., Kagawa S., Baxter R.C., Yang X.J., Gray S.G., Teh B.T. Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int. J. Oncol. 2005, 26:923-931.
28. Wang H., Rosen D.G., Fuller G.N., Zhang W., Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod. Pathol. 2006, 19:1149-1156.
29. Butt A.J., Dickson K.A., Jambazov S., Baxter R.C. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005, 146:3113-3122.
30. Butt A.J., Dickson K.A., McDougall F., Baxter R.C. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J. Biol. Chem. 2003, 278:29676-29685.
31. Akkiprik M., Feng Y., Wang H., Chen K., Hu L., Sahin A., Krishnamurthy S., Ozer A., Hao X., Zhang W. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res. 2008, 10:212.
32. Kalus W., Zweckstetter M., Renner C., Sanchez Y., Georgescu J., Grol M., Demuth D., Schumacher R., Dony C., Lang K., Holak T.A. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. Embo J. 1998, 17:6558-6572.
33. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195:127-137.
34. Beattie J., Allan G.J., Lochrie J.D., Flint D.J. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem. J. 2006, 395:1-19.
35. Song H., Shand J.H., Beattie J., Flint D.J., Allan G.J. The carboxy-terminal domain of IGF-binding protein-5 inhibits heparin binding to a site in the central domain. J. Mol. Endocrinol. 2001, 26:229-239.